Company research
IDEXX LABORATORIES INC /DE
CIK 874716Updated Sep 24, 2026
SecurityIDXX · NASDAQ · equity
IDXX price & chart
Loading TradingView…
NASDAQ:IDXX on TradingView ↗About the company
IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions - to advance medical care, improve efficiency, and build thriving practices. Our innovations also help measure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500 ™ Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit www.idexx.com.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 3,350,759,000Source | 3,293,443,000Source | 3,259,925,000Source | 2,746,765,000Source |
| Property, Plant and Equipment, NetUSD | 747,380,000Source | 713,123,000Source | 702,177,000Source | 649,474,000Source |
| GoodwillUSD | 414,004,000Source | 405,100,000Source | 365,961,000Source | 361,795,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 109,843,000Source | 111,676,000Source | 84,500,000Source | 97,672,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 180,070,000Source | 288,266,000Source | 453,932,000Source | 112,546,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 552,378,000Source | 473,575,000Source | 457,445,000Source | 400,619,000Source |
| Inventory, NetUSD | 377,756,000Source | 381,877,000Source | 380,282,000Source | 367,823,000Source |
| Assets, CurrentUSD | 1,413,827,000Source | 1,399,897,000Source | 1,495,254,000Source | 1,101,477,000Source |
| Operating Lease, Right-of-Use AssetUSD | 123,228,000Source | 116,129,000Source | 115,499,000Source | 118,618,000Source |
| Other Assets, NoncurrentUSD | 542,477,000Source | 547,518,000Source | 496,534,000Source | 417,729,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 1,745,376,000Source | 1,698,130,000Source | 1,775,395,000Source | 2,138,028,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 10,837,000Source | 10,784,000Source | 10,751,000Source | 10,719,000Source |
| Retained Earnings (Accumulated Deficit)USD | 6,391,902,000Source | 5,332,438,000Source | 4,444,571,000Source | 3,599,529,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -68,844,000Source | -93,645,000Source | -71,206,000Source | -77,796,000Source |
| Stockholders' Equity Attributable to ParentUSD | 1,605,383,000Source | 1,595,313,000Source | 1,484,530,000Source | 608,737,000Source |
| Additional Paid in Capital, Common StockUSD | 1,826,750,000Source | 1,673,863,000Source | 1,569,565,000Source | 1,463,215,000Source |
| Liabilities and EquityUSD | 3,350,759,000Source | 3,293,443,000Source | 3,259,925,000Source | 2,746,765,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 1,148,814,000Source | 1,067,916,000Source | 951,547,000Source | 1,235,803,000Source |
| Operating Lease, Liability, CurrentUSD | 27,074,000Source | 21,539,000Source | 19,802,000Source | 20,425,000Source |
| Accounts Payable, CurrentUSD | 110,408,000Source | 114,211,000Source | 110,643,000Source | 110,221,000Source |
| Operating Lease, Liability, NoncurrentUSD | 101,151,000Source | 97,836,000Source | 99,671,000Source | 101,239,000Source |
| Deferred Income Tax Liabilities, NetUSD | 31,865,000Source | 11,312,000Source | 7,235,000Source | 8,150,000Source |
| Other Liabilities, NoncurrentUSD | 56,527,000Source | 44,341,000Source | 65,526,000Source | 67,587,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 530,147,000Source | 502,119,000Source | 478,712,000Source | 433,662,000Source |
| Deferred Tax Liabilities, NetUSD | 3,994,000Source | — | — | — |
| Long-term Debt, Excluding Current Maturities | — | — | — | — |
| Long-term Debt, Current MaturitiesUSD | 74,995,000Source | 167,787,000Source | 74,997,000Source | 74,982,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 374,842,000Source | 449,786,000Source | 622,883,000Source | 694,387,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | 845,042,000Source | 679,089,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 145,183,000Source | 129,936,000Source | 114,908,000Source | 111,900,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 60,013,000Source | 60,295,000Source | 59,739,000Source | 49,770,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 68,722,000Source | 28,280,000Source | 53,871,000Source | 41,398,000Source |
| Increase (Decrease) in InventoriesUSD | 789,000Source | 28,001,000Source | 28,651,000Source | 121,731,000Source |
| Increase (Decrease) in Accounts PayableUSD | -8,573,000Source | 8,086,000Source | — | — |
| Deferred Income Tax Expense (Benefit)USD | 131,204,000Source | -24,194,000Source | -48,306,000Source | -34,883,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 1,181,805,000Source | 929,001,000Source | 906,510,000Source | 542,984,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 0Source | 76,694,000Source | 0Source | 11,512,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -136,239,000Source | -207,062,000Source | -125,254,000Source | -195,350,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 124,676,000Source | 120,922,000Source | 133,631,000Source | 148,838,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 7,239,000Source | 10,531,000Source | 9,975,000Source | 10,606,000Source |
| Payments for Repurchase of Common StockUSD | 1,216,964,000Source | 837,034,000Source | 71,920,000Source | 819,711,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -1,164,964,000Source | -878,073,000Source | -441,996,000Source | -370,936,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -108,196,000Source | -165,666,000Source | 341,386,000Source | -31,908,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 180,070,000Source | 288,266,000Source | 453,932,000Source | 112,546,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 37,700,000Source | 33,800,000Source | 41,000,000Source | 39,500,000Source |
| Income Taxes Paid, NetUSD | 167,498,000Source | 307,200,000Source | 192,500,000Source | 239,800,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 11,202,000Source | -9,532,000Source | 2,126,000Source | -8,606,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 60,013,000Source | 60,295,000Source | 59,739,000Source | 49,770,000Source |
| Amortization of Intangible AssetsUSD | 20,200,000Source | 17,100,000Source | 13,800,000Source | 15,000,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -4,200,000Source | -4,500,000Source | -1,100,000Source | -3,400,000Source |
| General and Administrative ExpenseUSD | 404,794,000Source | 442,291,000Source | 335,825,000Source | 326,248,000Source |
| GoodwillUSD | 414,004,000Source | 405,100,000Source | 365,961,000Source | 361,795,000Source |
| Goodwill, Impairment LossUSD | — | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | 0Source | 0Source | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | 264,725,000Source | 221,964,000Source | 216,134,000Source | 180,883,000Source |
| InterestExpenseNonoperatingUSD | 38,852,000Source | 31,205,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | 1,059,464,000Source | 887,867,000Source | 845,042,000Source | 679,089,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | 0Source | 0Source |
| Operating ExpensesUSD | 1,299,548,000Source | 1,250,590,000Source | — | — |
| Operating Lease, ExpenseUSD | 36,300,000Source | 32,400,000Source | 29,100,000Source | 26,800,000Source |
| Other Depreciation and AmortizationUSD | 124,947,000Source | 112,809,000Source | 100,994,000Source | 96,746,000Source |
| Provision for Loan, Lease, and Other LossesUSD | 8,429,000Source | 6,867,000Source | 5,552,000Source | 5,829,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 4,303,702,000Source | 3,897,504,000Source | 3,660,953,000Source | 3,367,324,000Source |
| Cost of RevenueUSD | 1,644,123,000Source | 1,518,577,000Source | 1,470,983,000Source | 1,362,986,000Source |
| Operating Income (Loss)USD | 1,360,031,000Source | 1,128,337,000Source | 1,097,128,000Source | 898,765,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 1,324,189,000Source | 1,109,831,000Source | 1,061,176,000Source | 859,972,000Source |
| Income Tax Expense (Benefit)USD | 264,725,000Source | 221,964,000Source | 216,134,000Source | 180,883,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | 1,059,464,000Source | 887,867,000Source | 845,042,000Source | 679,089,000Source |
| Earnings Per Share, BasicUSD per share | 13.17Source | 10.77Source | 10.17Source | 8.12Source |
| Earnings Per Share, DilutedUSD per share | 13.08Source | 10.67Source | 10.06Source | 8.03Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 80,427,000Source | 82,467,000Source | 83,066,000Source | 83,623,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 81,025,000Source | 83,246,000Source | 83,978,000Source | 84,600,000Source |
| Interest Expense (non-operating)USD | 38,852,000Source | 31,205,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 20,200,000Source | 17,100,000Source | 13,800,000Source | 15,000,000Source |
| Current Income Tax Expense (Benefit)USD | 133,521,000Source | 246,158,000Source | 264,440,000Source | 215,766,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -4,200,000Source | -4,500,000Source | -1,100,000Source | -3,400,000Source |
| General and Administrative ExpenseUSD | 404,794,000Source | 442,291,000Source | 335,825,000Source | 326,248,000Source |
| Goodwill, Impairment LossUSD | — | 0Source | 0Source | 0Source |
| Gross ProfitUSD | 2,659,579,000Source | 2,378,927,000Source | 2,189,970,000Source | 2,004,338,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 1,057,551,000Source | 897,336,000Source | 889,133,000Source | 684,661,000Source |
| Interest and Other IncomeUSD | 3,010,000Source | 12,699,000Source | 5,629,000Source | 1,065,000Source |
| Interest ExpenseUSD | — | — | 41,581,000Source | 39,858,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | -35,952,000Source | -38,793,000Source |
| Lease IncomeUSD | 15,800,000Source | 13,900,000Source | 20,700,000Source | 20,300,000Source |
| Operating ExpensesUSD | 1,299,548,000Source | 1,250,590,000Source | — | — |
| Operating Lease, ExpenseUSD | 36,300,000Source | 32,400,000Source | 29,100,000Source | 26,800,000Source |
| Research and Development ExpenseUSD | 251,207,000Source | 219,792,000Source | 190,951,000Source | 254,820,000Source |
| Selling and Marketing ExpenseUSD | 643,547,000Source | 588,507,000Source | 566,066,000Source | 524,505,000Source |
Filing attachments
tm2622041d1_ex99-1.htm · 8-K · 2026-08-04
EX-99.1 2 tm2622041d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 IDEXX Laboratories Announces Second Quarter Results Achieves second quarter revenue growth of 10% as reported and 9% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic. ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Strong volume-driven CAG Diagnostics recurring revenue growth including benefits from I…
Read attachment ↗tm2613510d1_ex99-1.htm · 8-K · 2026-05-05
EX-99.1 2 tm2613510d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 IDEXX Laboratories Announces First Quarter Results Achieves first quarter revenue growth of 14% as reported and 11% organic, and CAG Diagnostics recurring revenue growth of 14% as reported and 11% organic. ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Double-digit organic revenue growth was driven by IDEXX execution and commercial perform…
Read attachment ↗tm264623d1_ex99-1.htm · 8-K · 2026-02-02
EX-99.1 2 tm264623d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results Achieves fourth quarter revenue growth of 14% as reported and 12% organic, reflecting strong CAG Diagnostics recurring revenue, growing 12% reported and 10% organic. ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Strong organic growth benefits from IDEXX execution and co…
Read attachment ↗tm262817d1_ex99-1.htm · 8-K · 2026-01-13
EX-99.1 5 tm262817d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 IDEXX Announces CEO Succession Michael Erickson, PhD, to Succeed Jay Mazelsky as President and CEO; Mazelsky to Serve as Executive Chair of the Board of Directors WESTBROOK, Maine, January 13, 2026 - IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the promotion of Michael (Mike) Erickson, PhD, to President and Chief Executive Officer, effective May 12, 2026, at which time Jona…
Read attachment ↗tm2530045d1_ex99-1.htm · 8-K · 2025-11-03
EX-99.1 2 tm2530045d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 IDEXX Laboratories Announces Third Quarter Results Achieves third quarter revenue growth of 13% as reported and 12% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic. ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Strong organic revenue growth was supported by IDEXX execution and commercial performanc…
Read attachment ↗tm2528124d1_ex99-1.htm · 8-K · 2025-10-07
EX-99.1 2 tm2528124d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 IDEXX Laboratories Elects Karen Peacock to Board of Directors WESTBROOK, Maine, October 7, 2025 - IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the election of Karen Peacock to the Company’s Board of Directors, effective October 6, 2025. “We are extremely pleased to welcome Karen to the IDEXX Board of Directors,” said Lawrence D. Kingsley, the Company’s Independent Non-Execu…
Read attachment ↗